Drugs / 100 mg of humanized IgG4 mAb in 10 mL of isotonic solution
100 mg of humanized IgG4 mAb in 10 mL of isotonic solution
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07341360 | Oct 2025 → Dec 2029 expected | pseudomyxoma peritonei | Oslo University Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 100 mg of humanized IgG4 mAb in 10 mL of isotonic solution | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07341360 ↗ |
| Action | Inhibit | “PD-1 inhibitor tislelizumab” NCT07341360 ↗ |
| Modality | Monoclonal antibody | “humanized IgG4 mAb” NCT07341360 ↗ |